Amgen stock rises following FDA approval of UPLIZNA

Published 03/04/2025, 21:20
© Reuters.

Investing.com -- Shares of Amgen Inc (NASDAQ:AMGN) climbed 1.4% today after the company announced that the U.S. Food and Drug Administration (FDA) has approved its drug UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD). This approval positions UPLIZNA as the first and only FDA-approved treatment for this chronic and potentially debilitating condition, which can affect multiple organs and lead to irreversible damage.

The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in IgG4-RD, a disease characterized by immune-mediated inflammatory flares that can mimic other conditions. The approval is based on results from the MITIGATE trial, which demonstrated UPLIZNA’s ability to decrease disease activity by reducing flares while maintaining an established safety profile.

Jay Bradner, M.D., executive vice president of Research and Development at Amgen, expressed the company’s pride in delivering a therapy that significantly improves care for patients with IgG4-RD. He emphasized UPLIZNA’s potential in treating other immune-mediated diseases and Amgen’s commitment to developing innovative treatments targeting CD19+ B-cells.

John Stone, M.D., M.P.H., the principal investigator of the MITIGATE trial and a professor at Harvard Medical (TASE:BLWV) School, highlighted the effectiveness of targeting CD19+ B cells with UPLIZNA in addressing the pathophysiology of IgG4-RD. He pointed out the importance of raising disease awareness to ensure patients receive the right treatment early in their diagnostic journey.

This approval marks the second indication for UPLIZNA, which was previously approved for the treatment of adult patients with AQP4-IgG+ Neuromyelitis Optica Spectrum Disorder (NMOSD) in June 2020. The FDA has also granted the drug Orphan Drug Designation for the treatment of generalized myasthenia gravis (gMG), with regulatory filing activities for gMG expected to be completed in the first half of 2025.

Citi analyst Geoff Meacham reiterated a Neutral rating and a $295.00 price target on Amgen. He commented on the recent FDA approval, stating, "We think this approval likely adds incremental growth to Uplizna revenues (2025e $516M BBG cons) given its status as the only FDA-approved treatment for IgG4-RD."

Investors are responding to the news, reflecting optimism about Amgen’s potential to capitalize on the new treatment’s market exclusivity and its impact on the company’s revenue streams.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.